	US 12,263,189 B2
	Mesenchymal stem cell derived exosomes and methods
Patrick Soon-Shiong, Culver City, CA (US); Francesco Curcio, Culver City, CA (US); and Kayvan Niazi, Culver City, CA (US)
Assigned to NantBio, Inc., Culver City, CA (US)
Appl. No. 17/284,969
Filed by NantBio, Inc., Culver City, CA (US)
PCT Filed Oct. 17, 2019, PCT No. PCT/US2019/056804 § 371(c)(1), (2) Date Apr. 13, 2021, PCT Pub. No. WO2020/081859, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/747,605, filed on Oct. 18, 2018.
Prior Publication US 2021/0353684 A1, Nov. 18, 2021
Int. Cl. A61K 35/28 (2015.01); A61K 45/06 (2006.01)

CPC A61K 35/28 (2013.01) [A61K 45/06 (2013.01)]

7 Claims

1. A pharmaceutical composition for treating pain in a human in need thereof, comprising at least 10⁶adipose mesenchymal stem cell (AMSC) derived exosomes,

wherein the AMSC derived exosomes are stimulated by at least 10 ng/ml interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα), and

wherein the composition is in a syringe or catheter.